>>What clinical governance indicators do you suggest might represent poor
>>quality under prescribing?
>I'm still not sure what clinical governance means, but as prescribing
>indicators go significant underspends on cardiovascular or diabetes might
be
>worth investigation. At least one HA uses the proportion of chlorpropamide
+
>glibenclamide of total oral hypoglycaemics as an indicator.
>There's also steroid inhalers as a proportion of all inhalers which has
been
>used, but which seems to be falling out of favour with the advent of the
>COPD guidelines.
Would it be fair to say that HA's have not been so worried about their 50%
under national average practices as the 50% over ones?
I have heard the steroid inhaler % quoted before as a quality marker, but
not the glibenclamide one. So how are PCG's going to justify pressurising
the high cost practices when the art of assessing quality prescribing is so
underdeveloped?
Paul
>
>Regards
>
>Jeff Green
>
>==================================================
>Community Locum and Prescribing Support Pharmacist
>
>[log in to unmask]
>==================================================
>
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
|